Page contentsPage contentsKey factsDecisionKey facts Active Substance Izaflortaucipir (18F) Therapeutic area Neurology Decision number P/0432/2021 PIP number EMEA-003040-PIP01-21 Pharmaceutical form(s) Solution for injection Condition(s) / indication(s) Diagnosis of corticobasal degenerationTreatment of progressive supranuclear palsy Route(s) of administration Intravenous use Contact for public enquiries Life Molecular Imaging GmbHEmail: gra@life-mi.comTel. +49 30461124603 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 29/10/2021DecisionP/0432/2021 : EMA decision of 29 October 2021 on the granting of a product specific waiver for izaflortaucipir (18F) (EMEA-003040-PIP01-21)AdoptedReference Number: EMA/533649/2021 English (EN) (206.44 KB - PDF)First published: 21/02/2023ViewShare this page